As an extremely aggressive form of skin cancer, cutaneous melanoma, is still associated with a high mortality rate. Enormous progress has recently been made in the fight against deadly metastasis, but existing therapeutic ...
Nov 21, 2023
0
24
A new editorial paper titled "The uncharted role of HER2 mutant alleles in breast cancer has been published in Oncotarget.
Nov 6, 2023
0
1
In a recent study published in Leukemia, Finnish researchers investigated why some patients with chronic myeloid leukemia (CML) can discontinue their daily medication safely.
Nov 6, 2023
0
0
Ripretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced gastrointestinal stromal tumor (GIST) in patients who received prior treatment with three or more tyrosine ...
Nov 6, 2023
0
0
Researchers have revealed a new mechanism of targeted drug treatment used against chronic lymphocytic leukemia, through the promotion of immune cell function, that could be exploited using new anti-cancer immunotherapies.
Oct 19, 2023
0
0
Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of which is guided by biomarker testing.
Oct 18, 2023
0
0
For certain patients with advanced breast cancer, a drug called Piqray (alpelisib) may extend survival. But new research confirms the medication often causes seriously high blood sugar levels.
Sep 25, 2023
0
8
A new editorial paper titled "Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma" has been published in Oncotarget.
Sep 20, 2023
0
1
A new editorial paper titled "Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?" has been published in Oncotarget.
Sep 13, 2023
0
1
A new editorial paper titled "Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer" has been published in Oncotarget.
Sep 11, 2023
0
13
